肌红蛋白与肌酸激酶比值提高横纹肌溶解症急性肾损伤预测
这项前瞻性多中心队列研究在挪威奥斯陆和阿克什胡斯四家医院纳入310例急诊就诊或72小时内肌酸激酶≥5000 U/L和/或肌红蛋白≥1000 ng/mL的成人患者,108例(35%)发生急性肾损伤。受试者工作特征分析显示,肌红蛋白与肌酸激酶比值是入院时最强的急性肾损伤预测指标(曲线下面积0.84,95%CI 0.79至0.89),优于肌红蛋白(0.73,95%CI 0.67至0.79),肌酸激酶预测能力弱(0.31,95%CI 0.25至0.37)。比值≥0.20提示风险,最高四分位组72%发生急性肾损伤;肌红蛋白≥6372 ng/mL提示风险,最高四分位组65%发生急性肾损伤。优化界值为比值0.48(敏感度/特异度79/82%)和肌红蛋白4489 ng/mL(61/76%),两者联合将敏感度和阴性预测值分别提高至89%(95%CI 81.3%至94.4%)和92%(95%CI 86.2%至96.0%)。
要点
- 在310例横纹肌溶解症患者中,108例(35%)发生急性肾损伤,入院时肌红蛋白与肌酸激酶比值是急性肾损伤最强预测指标(曲线下面积0.84,95%CI 0.79至0.89)。
- 肌红蛋白与肌酸激酶比值≥0.20提示急性肾损伤风险,最高四分位组72%发生急性肾损伤;肌红蛋白≥6372 ng/mL提示风险,最高四分位组65%发生急性肾损伤。
- 优化界值为比值≥0.48(敏感度79%、特异度82%)联合肌红蛋白≥4489 ng/mL(敏感度61%、特异度76%),联合后敏感度89%(95%CI 81.3%至94.4%)、阴性预测值92%(95%CI 86.2%至96.0%)。
- 肌酸激酶单独预测急性肾损伤能力弱(曲线下面积0.31,95%CI 0.25至0.37),肌红蛋白次之(0.73,95%CI 0.67至0.79)。
- 作者认为该比值联合肌红蛋白可作为入院时早期急性肾损伤风险分层工具,识别高危和低危患者。
适用人群与场景
- 挪威奥斯陆和阿克什胡斯四家医院2019至2022年前瞻性纳入的成人患者,急诊就诊时或72小时内肌酸激酶≥5000 U/L和/或肌红蛋白≥1000 ng/mL,不论是否住院。
诊断标准与关键阈值
- 肌红蛋白与肌酸激酶比值≥0.20提示急性肾损伤风险。
- 肌红蛋白≥6372 ng/mL提示急性肾损伤风险。
- 优化界值:肌红蛋白与肌酸激酶比值≥0.48(敏感度79%、特异度82%),肌红蛋白≥4489 ng/mL(敏感度61%、特异度76%)。
- 比值≥0.48联合肌红蛋白≥4489 ng/mL:敏感度89%(95%CI 81.3%至94.4%),阴性预测值92%(95%CI 86.2%至96.0%)。
研究设计与关键结果
- 前瞻性多中心队列研究,纳入310例成人患者,108例(35%)发生急性肾损伤。
- 受试者工作特征分析:肌红蛋白与肌酸激酶比值曲线下面积0.84(95%CI 0.79至0.89),肌红蛋白0.73(95%CI 0.67至0.79),肌酸激酶0.31(95%CI 0.25至0.37)。
- 四分位分析:比值最高四分位组72%发生急性肾损伤,肌红蛋白最高四分位组65%发生急性肾损伤。
- 比值≥0.48联合肌红蛋白≥4489 ng/mL的敏感度89%(95%CI 81.3%至94.4%),阴性预测值92%(95%CI 86.2%至96.0%)。
证据类型、等级与局限
- 证据类型:前瞻性多中心队列研究,试验注册号NCT04118608。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,入院时肌红蛋白与肌酸激酶比值联合肌红蛋白水平可作为横纹肌溶解症患者早期急性肾损伤风险分层工具,帮助识别高危和低危患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute kidney injury (AKI) is a key complication of rhabdomyolysis. Creatine kinase (CK), the standard muscle injury biomarker, has limited predictive value. Myoglobin may be more accurate but has its limitations. The myoglobin-to-CK ratio may be a stronger predictor but lacks prospective validation. We aimed to validate this ratio using admission values, compare it with CK and myoglobin, and identify thresholds for early AKI risk stratification.
METHODS: Prospective multicentre cohort study across four hospitals in Oslo and Akershus, Norway (2019-2022). All adults with CK ≥5000 U/L and/or myoglobin ≥1000 ng/mL at emergency department presentation or within 72 hours thereafter were eligible, irrespective of admission. Primary outcome was AKI. Predictive performance of CK, myoglobin and the myoglobin-to-CK ratio was assessed using logistic regression and receiver operating characteristic (ROC) analysis.
RESULTS: In the 310 included patients, 108 (35%) developed AKI. In ROC analysis the myoglobin-to-CK ratio was the strongest predictor of AKI on admission (area under the curve (AUC) 0.84, 95% CI 0.79 to 0.89), followed by myoglobin (AUC 0.73, 95% CI 0.67 to 0.79); CK was a weak predictor (AUC 0.31, 95% CI 0.25 to 0.37). In quartile analysis, 72% of patients in the highest ratio quartile developed AKI, with a ratio ≥0.20 indicating risk. For myoglobin, 65% in the highest quartile developed AKI, with values ≥6372 ng/mL indicating risk. ROC analysis identified optimised cut-offs of 0.48 for the ratio (sensitivity/specificity 79/82%) and 4489 ng/mL for myoglobin (61/76%). Combined, these cut-offs increased sensitivity and negative predictive value to 89% (95% CI 81.3% to 94.4%) and 92% (95% CI 86.2% to 96.0%), respectively, suggesting potential for identification of both high-risk and low-risk patients at admission.
CONCLUSIONS: The myoglobin-to-CK ratio was the strongest early predictor of AKI. Combined with myoglobin ≥4489 ng/mL, a ratio ≥0.48 identified 89% of AKI cases and ruled out 92% of non-AKI cases, suggesting a potential admission-based tool for early AKI risk stratification in rhabdomyolysis.
TRIAL REGISTRATION NUMBER: NCT04118608.
参考来源
- Vangstad M, Gulsvik AK, Kro Birkeland JA, et al. Myoglobin-to-creatine kinase ratio enhances prediction of acute kidney injury in rhabdomyolysis. Emerg Med J. 2026. PMID: 41605622. doi:10.1136/emermed-2025-215470
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。